Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TVTX
HOLDTravere Therapeutics, Inc. · Healthcare · United States · $5.3B · Avg Vol: $107M/d
COMPANY DESCRIPTION
Travere Therapeutics, Inc. is a biopharmaceutical company focused on identifying, developing, and delivering life-changing therapies for people living with rare kidney and metabolic diseases. The company's primary commercial product, Filspari (sparsentan), is approved for reducing proteinuria in adults with primary IgA nephropathy. Travere's competitive position is secured by its specialized orphan drug pipeline, strong patient advocacy relationships, and targeted commercial execution.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 109.5M | 145.2M | 233.2M | 490.7M | 64.9% | 536.2M | 696.0M | 963.8M | 40.1% |
| EPS | -4.37 | -1.50 | -4.08 | -0.29 | — | -0.49 | — | — | — |
| Shares | 64.3M | 75.4M | 87.5M | 90.9M | +41.4% | 93.0M | — | — | — |
| Debt | 407.5M | 404.8M | 401.6M | 328.7M | -6.9% | 327.7M | — | — | — |
| Equity | 42.9M | 200.8M | 59.1M | 114.8M | 38.9% | — | — | — | — |
| Op CF | -186.3M | -280.0M | -237.5M | 37.8M | — | 39.6M | — | — | — |
| Inv CF | -32.6M | 55.8M | 99.3M | 27.9M | — | — | — | — | — |
| Fin CF | 117.6M | 218.8M | 139.4M | -33.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TVTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TVTX | Travere Therapeutics, Inc.(you) | $5.3B | 48 | HOLD |
| PTCT | PTC Therapeutics, Inc. | $6.4B | 46 | HOLD |
| MIRM | Mirum Pharmaceuticals, Inc. | $6.9B | 47 | HOLD |
| ELVN | Enliven Therapeutics, Inc. | $3.8B | 45 | HOLD |
| 0HI3.L | Arrowhead Pharmaceuticals, Inc. | $8.4B | 47 | HOLD |
| 0HKF.L | Axsome Therapeutics, Inc. | $7.7B | 45 | HOLD |
| DFTX | Definium Therapeutics, Inc. | $5.7B | 39 | HOLD |
| PTGX | Protagonist Therapeutics, Inc. | $8.8B | 50 | HOLD |
| ORKA | Oruka Therapeutics, Inc. | $5.6B | 35 | SELL |
| DNTH | Dianthus Therapeutics, Inc. | $5.7B | 35 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.5%